Cabozantinib as a second-line treatment option in hepatocellular carcinoma.

Alberto D'AngeloNavid SobhaniStefan BagbyAndrea Casadei-GardiniGiandomenico Roviello

Published in: Expert review of clinical pharmacology (2020)

Despite the recent achievements in the use of cabozantinib for patients diagnosed with hepatocellular carcinoma, data are still needed to allow clinicians to make better decisions on how to treat specific patient subgroups.

Keyphrases

ejection fraction
newly diagnosed
prognostic factors
palliative care
case report
electronic health record
machine learning
deep learning
patient reported
data analysis
replacement therapy